Myriad Genetics disclosed an IT network breach on November 2, leading to a temporary shutdown of testing operations and order management systems. While most systems are now operational and the company doesn't foresee a material adverse effect, the incident's full scope, including potential patient data compromise, is still under investigation. This could lead to short-term operational disruptions and reputational damage.
Myriad Genetics reported unauthorized access to its IT network, which occurred on November 2, 2026. This cyber incident forced the company to temporarily suspend its testing operations and order management systems, directly impacting its core business functions. While most systems have reportedly returned to normal, the investigation into the breach's extent and potential patient data compromise is ongoing. This event is significant for MYGN as it poses immediate operational risks, potential regulatory fines if patient data was exposed, and reputational damage, even if the company currently believes the financial impact won't be material. Traders should monitor for updates on the investigation's findings, particularly regarding data breaches, as this could escalate the negative impact.